Lincoln, Nebraska: LI-COR is working with BellBrook Labs to create competitive immunoassay kits for high-throughput screening (HTS). Building upon the success of prior incorporation of LI-COR’s IRDye® QC-1 quencher conjugate into its Transcreener® ADP2 FI Assay, BellBrook Labs has chosen to use the same quencher conjugate in its Transcreener GDP FI Assay. The Transcreener GDP FI Assay is designed specifically for HTS and uses a highly specific, proprietary antibody for GDP, meaning that it can be used with any enzyme that converts GTP to GDP. The Transcreener GDP Detection Mixture is comprised of a GDP Alexa Fluor® 594 Tracer bound to the GDP Antibody conjugated to LI-COR’s IRDye® QC-1 quencher conjugate. Measurement of GDP is done with red fluorescent intensity (FI) readout.

“IRDye QC-1 efficiently quenches a wide range of both visible and near-infrared dyes,” says Jeff Harford, LI-COR senior marketing project manager. “Its use in the BellBrook Labs Transcreener assay is an important step in adding application versatility to the IRDye QC-1 product portfolio.”

LI-COR’s IRDye QC-1 is the first non-fluorescent quencher compatible with a wide range of visible and near-infrared (NIR) fluorophores (approximately 500-800 nm). It can be paired with any visible or NIR fluorophore within its wide wavelength range and quenches with greater than 97 percent efficiency. It is commonly used for fluorescence resonance energy transfer (FRET) applications, such as protease assays.

“The Transcreener GDP FI Assay is a sensitive, homogeneous, fluorescent assay for direct detection and screening of GTPases, monomeric small G protein family members, whose regulation is important in many signal transduction pathways and diseases, including cancer,” says Dr. Robert Lowery, BellBrook Labs president & CEO. “It features a single mix-and-read format, excellent deck and signal stability, and is compatible with most commonly used plate readers.”

BellBrooks Labs – BellBrook Labs, LLC develops detection reagents and microfluidic devices that accelerate the discovery of more effective therapies for cancer and other debilitating diseases. Transcreener® is a patented high-throughput screening assay platform that was introduced in 2005 and is used to identify inhibitors for kinases and other types of protein drug targets. The iuvo™ Microconduit Array technology and assay screening service is a line of unique microscale devices for miniaturization and automation of advanced cell models that are more representative of human physiology. Visit BellBrook’s website for more information: www.bellbrooklabs.com.